Plenary Sessions-01/05/2021

Saturday, May 1st, 2021

8:30 – 10:45

Plenary session 3: Hematological malignancies

Chairs: H. Ten Cate (The Netherlands), F. Rodeghiero (Italy)

PL-10 - Risk-assessment of thrombosis and bleeding in hematological malignancies
B. Brenner (Israel)

PL-11 - Advances in management of coagulopathy in APL
M.A. Sanz (Spain)

PL-12 - Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia
A. Leader (Israel)

PL-13 - Multiple myeloma-associated VTE risk prediction
K. Sanfilippo (USA)

Selected Abstract

OC-05 - The Molecular Mechanisms of Ponatinib-Induced Thrombosis
A.H. Schmaier, A.A. Merkulova, E.R. Chan, E.X. Stavrou, S.C. Mitchell, G.L. Forbes, P. Zeng (USA)

OC-06 - Differences in Thromboprophylaxis Between Hospitalized Patients with Solid or Hematological Malignancies
R. Figueroa, M. Marcos-Jubilar, A. García-Mouriz, J.A. Páramo, R. Lecumberri (Spain)

10:45 - 11:15

Coffee Break

11:15 – 12:15

Plenary Lecture: 6th Simon Karpatkin Memorial Lecture

Chairs: A. Falanga (Italy); B. Brenner (Israel); A.A. Khorana (USA)

Introduction to Lecture
F.R. Rickles (USA)

Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer - past, present and future
I. Pabinger (Austria)
 

12:15 – 13:15

Roundtable: Emerging practical guidelines for the prevention and treatment of CAT

Chairs: M. Cattaneo (Italy), R. Labianca (Italy)

Introduction: Overview of VTE treatment and prevention in cancer according to clinical guidelines
G. Lyman (USA)

Discussant: G. Lyman (USA)I. Elalamy (France), A. Falanga (Italy), D. Farge (France), K. Jordan (Germany), A. Lee (Canada)

13:15 - 14:15

Lunch Sessions

14:15 - 16:15

Poster Sessions with coffee and pastries

16:15 – 18:00

Plenary Session 4: Prevention of VTE in cancer patients

Chairs: P. Prandoni (Italy), J.A. Paramo (Spain)

PL-14 - Inpatient thromboprophylaxis in cancer patients: what is the evidence?
J. Zwicker (USA)

PL-15 - Roles of LMWH for prevention in cancer patients
A. Maraveyas (UK)

PL-16 - Meta-analysis and systematic review of NOAC prophylaxis in high risk cancer outpatients
N. Kuderer (USA) 

Selected Abstract

OC-07 - D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial
S. Vadhan-Raj, N. Kuderer, T. Wun, J. Patel, K. McCrae, X. Zhou, U. Vijapurkar, C.V. Damaraju, P. Wildgoose, G. Lyman, A.A. Khorana (USA)

OC-08 - A clinical-genetic risk score to predict cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts
A. Muñoz, C. Ay, E. Grilz, S. López, C. Font, V. Pachón, V. Castellón, V. Martínez-Marín, M. Salgado, E. Martínez, J. Calzas, A. Rupérez, E. Salas, I. Pabinger, J.M. Soria (Spain, Austria)

 

18:00 – 19:00

Debate: Outpatient prophylaxis: are we there yet?

Chairs: G. Agnelli (Italy), C. Francis (USA)

NO: H. Buller (The Netherlands)

YES: A.A. Khorana (USA)